$6.87
+2.6%Artiva Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing natural killer (NK) cell-based therapies for patients suffering from autoimmune diseases and cancers. The company's lead product candidate is AB-101, an off-the-shelf NK cell therapy for patients with autoimmune diseases and cancers, such as lupus nephritis, rheumatoid arthritis, pemphigus vulgaris, the anti-neutrophil cytoplasmic antibody-associated vasculitis subtypes granulomatosis with polyangiitis/microscopic polyangiitis, systemic lupus erythematosus, and B-cell-non-Hodgkin lymphoma. It also develops AB-201, an allogeneic anti- human epidermal growth factor receptor 2 chimeric antigen receptor (CAR)-NK cell product candidate; and AB-205, an allogeneic anti-CD5 CAR-NK cell product candidate. The company was incorporated in 2019 and is headquartered in San Diego, California.
Chief Financial Officer & Executive Vice President of Corporate Development
Compensation
$595,515
Chief Medical Officer
Chief Technical Operations Officer
Compensation
$612,234
Co-Founder & Strategic Advisor
Compensation
$499,368
Executive Vice President, Chief Operating Officer, Chief Legal Officer, Corporate Secretary & Compliance Officer
Compensation
$676,166
President, Chief Executive Officer & Director
Compensation
$963,111
Senior Vice President of Biometrics
Senior Vice President of Clinical Operations
Senior Vice President of Regulatory Affairs
Senior Vice President of Research & Early Development
During the last 12 months, insiders have purchased $87.65M and sold $732K worth of ARTV shares, resulting in $86.92M of net buying activity.
7.6M
87.50M
53.0K
477.77K
+87.0M
+$87.02M
0
0.00
3.2K
19.12K
-19K
-$19K
0
0.00
31.9K
174.52K
-175K
-$175K
96.3K
154.96K
21.9K
60.25K
+95K
+$95K
Ra Capital Management, L.P.
Director, 10 Percent Owner:
$75.02M
Gc Corp.
10 Percent Owner
$12.50M
Daniels Brian
Director
$22K
Moore Alison
Director
$22K
Baker Daniel G.
Director
$22K
Aslan Fred
Director, Officer: Chief Executive Officer
$450K
Bush Jennifer
Officer: Coo, Clo, Compliance Officer
$97K
Horan Christopher
Officer: Chief Tech Operations Officer
$73K
Banerjee Subhashis
Officer: Chief Medical Officer
$63K
Raymon Heather
Officer: Svp, Research And Development
$32K
Strong bullish signal with $86.92M net buying. Insiders are aggressively accumulating shares, suggesting significant confidence in future prospects.
Exceptional buy/sell ratio. Buying dramatically outweighs selling—one of the strongest possible insider signals.
Very strong recent buying momentum. Recent insider purchases significantly outpace sales, suggesting near-term optimism.
5 insider buyers and 5 sellers. Equal participation suggests mixed or neutral insider views.
Strong confluence of bullish signals: High buy/sell ratio, multiple insiders participating, and recent buying momentum all point to significant insider confidence. This level of coordinated buying often precedes positive developments.
ARTV - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
DEF 14A DEF 14A 2025 N/A | April 29, 2025 | June 24, 2025 | 2025 |
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.